Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Core Insights - Merck announced positive new data for ENFLONSIA™ (clesrovimab), indicating its effectiveness for infants and children under 2 years old at increased risk for severe RSV over two RSV seasons [1] Group 1 - The data highlights the potential of ENFLONSIA™ to significantly reduce the risk of severe respiratory syncytial virus (RSV) in vulnerable pediatric populations [1] - The announcement is expected to enhance Merck's position in the pediatric infectious disease market, particularly in the context of RSV treatment [1] - This development may lead to increased interest from healthcare providers and potential partnerships for further research and distribution [1]